Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305, and *Department of Biology, Ochanomizu University, Bunkyo-ku, Tokyo 112, Japan ABSTRACT Vitronectin (also called S-protein, serum spreading factor, or epibolin) is one of two major cell-adhesive glycoproteins in mammalian plasma and serum (3, 10, 13, 20, 36) ; the other is fibronectin. Vitronectin is a monomeric glycoprotein detected as a mixture of 75 kilodalton (kDa) and 65 kDa polypeptides; the latter seems to be an endogenously proteolytically nicked product of the former (1, 3, 6, 13) . Vitronectin binds to heparin (13) , collagen (9, 16) , thrombin-antithrombin III complex (15, 17, 27, 30) , C5b-9 complex (25), streptococci (5, 8) , and a variety of cultured cells. The cell-binding site of vitronectin involves a common cell-attachment tripeptide Arg-Gly-Asp (32, 37) . Although the primary structure, cDNA sequence (18, 37) , and domain structure (38) are known, published purification procedures for vitronectin are relatively cumbersome and inefficient. Human plasma and serum contain 10-40 mg of vitronectin per 100 ml (3, 13, 34) , but only a few mg or less of vitronectin can be isolated with a 0.5-20% recovery efficiency through very long processes (3, 6, 28, 29, 35) or with a very expensive, commercially available monoclonal antibody (13, 38 the vitronectin in serum and plasma was lost by its binding to the pre-column of heparin-Sepharose in the absence of 8 M urea. The following variations resulted in substantially similar elution profiles and recovery efficiencies for vitronectin. Serum passed through the pre-column could be directly treated with Buffer A containing 0.13 M NaC1 instead of with 8 M urea and distilled water. The absence of divalent cations was not essential during the procedure, because 10 mM MgC12, 1 mM CaC12, and 20 mM Tris-HCI (pH 8.0) could be substituted for 5 mM EDTA and 10 mM Na-phosphate buffer (pH 7.7) in Buffer A. Plasma and serum were ultimately diluted two or three fold before passage over the heparin-Sepharose column used for the isolation step. This dilution reduced the viscosity of plasma which increased after the addition of 8 M urea, but the dilution might not be essential for the isolation. One mM dithiothreitol could also be substituted for the 10 mM 2-mercaptoethanol. Plasma, which was fibronectindepleted by gelatin-Sepharose affinity chromatography, produced a similar preparation of vitronectin. Serum or fibrinogen-depleted plasma in 8 M urea could be boiled for 5 min instead of standing for 2 h to save time, and this procedure did not Fig. 2 . SDS-polyacrylamide gel electrophoresis of the fractions from the second heparin-Sepharose affinity column. Human plasma was clotted, the resulting serum adjusted to a final concentration of 8 M urea, and this applied to a heparin-Sepharose affinity column as described in the legend to Fig. 1 . The plasma, the serum obtained from the plasma, and the four protein peaks seen in Fig. 1 were analyzed by SDS-polyacrylamide gel electrophoresis after chemical reduction; (a) plasma, (b) serum, (c) flow-through fraction, (d) fraction eluted with Buffer A containing 0.13 M NaCl indicated by arrow "a" in Fig. 1 , (e) fraction eluted with Buffer A containing 0.13 M NaC1 and 10 mM 2-mercaptoethanol indicated by arrow "b" in Fig . 1 , and (f) purified vitronectin eluted with Buffer A containing 0.5 M NaCl indicated by arrow "c" in Fig . 1 method reported here (Fig. 4, d ) and on that purified by the Barnes procedure (Fig.  4, c) were indistinguishable. The shape of the cells on vitronectin was remarkably different from that of those on fibronectin (Fig. 4, b) . On fibronectin, the BHK cells were much more extended. To examine which protein was dominant in a mixed protein assay, cell spreading was examined on plates double-coated with vitronectin and fibronectin at various concentrations. Judging from the morphologies of the spread cells, the action of fibronectin predominated at the higher protein concentrations (Table 2) .
DISCUSSION
The simple, rapid, and inexpensive purification method for vitronectin reported here provides a powerful tool for further analysis of the biochemistry and cell biology of vitronectin.
This method may be scaled up for commercial purposes without any apparent problems. We have already been able to purify 45 mg of vitronectin from 2 liters human plasma within 3 days by this method. This method can also be applied to other biological fluids from any animal species, such as bovine, horse, rabbit, chicken, and porcine plasma (41).
Ruoslahti's group has been able to isolate 2-4 mg vitronectin per 100 ml human plasma by a combination of two chromatographic steps involving monoclonal antivitronectin antibody-Sepharose and heparin-Sepharose columns (13, 38) , while Barnes' group has been able to isolate approximately 2.5 mg vitronectin per 100-150 ml human serum by a sequence of chromatography using glass beads, DEAEcellulose, concanavalin A-Sepharose, and heparin-agarose (3, 35) . The former procedure isolates a heparin-binding form, while the latter isolates a non-heparinbinding form. The very simple method reported here isolates a form similar to that from Ruoslahti's preparation and the yield is 3-6 mg vitronectin per 100 ml human plasma.
Non-heparin-binding vitronectin acquires heparin-binding activity after treatment (2, 11) . This conversion was induced during the vitronectin purification procedure reported here. Thus, vitronectin in serum also acquires heparin-binding activity after 8 M urea treatment. It is, however, unknown why approximately 2/3 of the vitronectin in human serum which passed through the pre-column was not bound to the heparin-Sepharose in the presence of 0.13 M NaC1 and 8 M urea. A longer treatment of 2 days or boiling for 5 min in 8 M urea did not increase the binding efficiency. Vitronectin is known to form a complex with thrombin-antithrombin III in serum but not in plasma (15, 17, 27, 30) . The purification procedure reported here produced no substantial differences between the elution profiles for, purities of, or recovery efficiencies for vitronectin from plasma and serum. Therefore, the complex formation of vitronectin with thrombin-antithrombin III causes neither serious problems in the purification procedure nor the low binding efficiency mentioned above.
We also do not understand why a number of serum proteins interacted with the heparin-Sepharose in the absence but not in the presence of the reducing agent. The interaction was not specific since a number of the serum proteins could then be eluted with the reducing agent. As vitronectin tends to form disulfide bridges itself (6), a number of serum proteins may interact with vitronectin through its reactive SH groups but not with the heparin-Sepharose.
We have recently reported that human plasma and serum can be classified into three distinct types determined by the ratio of the 75 kDa to 65 kDa vitronectin (Table 2) , the poor spreading was also not the result of a tighter adhesion of cells to vitronectin-coated substrates. Nagata et al. (26) reported that collagen inhibits BHK cell spreading on fibronectin-coated substrates. Vitronectin, however, did not modulate it.
Boiling vitronectin for 5 min in the absence or presence of 8 M urea did not impair the spreading activity of vitronectin. This striking heat-resistance of vitronectin conflicts with a previous report by Barnes et al. (4) . In contrast, fibronectin lost all of its cell-spreading activity after boiling.
From the differences mentioned above, the molecular mechanism of cell spreading mediated by vitronectin may involve not only different receptors (31) , but also a mechanism distinct from that used by fibronectin.
